b GS-5806 is a small-molecule inhibitor of human respiratory syncytial virus fusion protein-mediated viral entry. During viral entry, the fusion protein undergoes major conformational changes, resulting in fusion of the viral envelope with the host cell membrane. This process is reproduced in vitro using a purified, truncated respiratory syncytial virus (RSV) fusion protein. GS-5806 blocked these conformational changes, suggesting a possible mechanism for antiviral activity. R espiratory syncytial virus (RSV) is an enveloped, singlestranded, negative-sense RNA virus that belongs to the Pneumovirinae subfamily of Paramyxoviridae (1). RSV infects the respiratory tract of infants, young children, and immunocompromised adults, causing severe disease (2-11). GS-5806 is a small-molecule inhibitor of RSV replication that is active against a diverse collection of RSV A and RSV B clinical isolates, with a mean 50% effective concentration (EC 50 ) of 0.43 nM (12, 13). GS-5806 blocks RSV fusion (F) protein-mediated cell-cell fusion, and mutations that confer drug resistance map to the RSV F gene, suggesting that the target of GS-5806 is the RSV F protein. Viral-cell membrane coalescence mediated by paramyxovirus fusion proteins involves several proteins, such as an attachment protein, cell surface receptors, and other cellular components that trigger conformational changes in the fusion protein that catalyze fusion of the two membranes (14-16). In vitro, triggering of preto postfusion conformational changes of RSV F proteins can be achieved by lowering the ionic strength of the buffer or by increasing the temperature (17-19). The conformational changes expose the buried hydrophobic fusion peptides, which interact with fusion peptides of neighboring molecules to form rosette-like structures (see Fig. S2 , top panel, in the supplemental material). These macromolecular structures are distinct and easily observed by electron microscopy (EM). The conformational changes can also be triggered in the presence of liposomes prepared in low-ionic-strength buffer. The RSV F protein triggered in the presence of liposomes inserts into the lipid bilayer presumably mediated by the fusion peptides. To evaluate the effects of GS-5806 on the pre-to postfusion conformational changes of RSV F, we expressed the extracellular domain of RSV F protein (⌬TM-RSV F) in HEK293 cells. The protein was stored in high-ionic-strength buffer (500 mM NaCl, 250 mM imidazole, 20 mM Tris, pH 8.0) to keep it in pretriggered conformation. On exposure to low-ionic-strength buffer (10 mM HEPES, pH 8.0) (see Fig. S1 in the supplemental material), ⌬TM-RSV F formed rosettes or inserted into liposomes that were easily observable by EM (see Fig. S2 , bottom panel, in the supplemental material). These experiments were used to measure the effect of GS-5806 on the conformational changes of ⌬TM-RSV F protein (18).
GS-5806 is a small-molecule inhibitor of human respiratory syncytial virus fusion protein-mediated viral entry. During viral entry, the fusion protein undergoes major conformational changes, resulting in fusion of the viral envelope with the host cell membrane. This process is reproduced in vitro using a purified, truncated respiratory syncytial virus (RSV) fusion protein. GS-5806 blocked these conformational changes, suggesting a possible mechanism for antiviral activity.
R
espiratory syncytial virus (RSV) is an enveloped, singlestranded, negative-sense RNA virus that belongs to the Pneumovirinae subfamily of Paramyxoviridae (1) . RSV infects the respiratory tract of infants, young children, and immunocompromised adults, causing severe disease (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . GS-5806 is a small-molecule inhibitor of RSV replication that is active against a diverse collection of RSV A and RSV B clinical isolates, with a mean 50% effective concentration (EC 50 ) of 0.43 nM (12, 13) . GS-5806 blocks RSV fusion (F) protein-mediated cell-cell fusion, and mutations that confer drug resistance map to the RSV F gene, suggesting that the target of GS-5806 is the RSV F protein. Viral-cell membrane coalescence mediated by paramyxovirus fusion proteins involves several proteins, such as an attachment protein, cell surface receptors, and other cellular components that trigger conformational changes in the fusion protein that catalyze fusion of the two membranes (14) (15) (16) . In vitro, triggering of preto postfusion conformational changes of RSV F proteins can be achieved by lowering the ionic strength of the buffer or by increasing the temperature (17) (18) (19) . The conformational changes expose the buried hydrophobic fusion peptides, which interact with fusion peptides of neighboring molecules to form rosette-like structures (see Fig. S2 , top panel, in the supplemental material). These macromolecular structures are distinct and easily observed by electron microscopy (EM). The conformational changes can also be triggered in the presence of liposomes prepared in low-ionic-strength buffer. The RSV F protein triggered in the presence of liposomes inserts into the lipid bilayer presumably mediated by the fusion peptides. To evaluate the effects of GS-5806 on the pre-to postfusion conformational changes of RSV F, we expressed the extracellular domain of RSV F protein (⌬TM-RSV F) in HEK293 cells. The protein was stored in high-ionic-strength buffer (500 mM NaCl, 250 mM imidazole, 20 mM Tris, pH 8.0) to keep it in pretriggered conformation. On exposure to low-ionic-strength buffer (10 mM HEPES, pH 8.0) (see Fig. S1 in the supplemental material), ⌬TM-RSV F formed rosettes or inserted into liposomes that were easily observable by EM (see Fig. S2 , bottom panel, in the supplemental material). These experiments were used to measure the effect of GS-5806 on the conformational changes of ⌬TM-RSV F protein (18) .
⌬TM-RSV F protein was triggered in the presence of GS-5806 (5-fold molar excess over protein), an inactive analog of GS-5806 (GSC-1), or 0.1% dimethyl sulfoxide (DMSO). The number of rosettes observed in 6 to 8 random EM images was quantified by visual inspection. The average number of rosettes per image in the DMSO-(control), GSC-1-, and GS-5806-treated samples was 108, 106, and 23, respectively. The decrease in the number of rosettes formed in the presence of GS-5806 was significant compared to that with the GSC-1-treated (P Ͻ 0.002) or DMSOtreated (P Ͻ 0.002) samples (Fig. 1A) . The inhibitory effect of GS-5806 was dose dependent, with fewer rosettes observed with increasing concentrations of GS-5806 (Fig. 1B ).
An RSV F resistance variant that contains a threonine-to-alanine amino acid change at position 400 of the RSV F protein was selected in vitro (12) . ⌬TM-RSV F T400A protein purified in the prefusion conformation was also triggered by low-ionic-strength buffer in a manner similar to that in the wild-type protein, but this process could not be inhibited by GS-5806. The numbers of rosettes formed in the presence of 0.1% DMSO (44 Ϯ 9) and GS-5806 (46.6 Ϯ 8) were similar (Fig. 1C) , consistent with the reduced efficacy of GS-5806 observed in RSV variants expressing the T400A protein.
The effect of GS-5806 on ⌬TM-RSV F protein conformational change was further evaluated by a liposome binding experiment. In order to increase the chances of insertion into the lipid bilayer and to avoid rosette formation, the liposome concentration was kept high (ϳ8 mM, 3,000-fold excess relative to RSV F). During the triggering process, RSV F molecules inserted into a few liposomes rather than partitioning evenly across all of the liposomes. The number of liposomes containing ⌬TM-RSV F protein mole-cules was quantified by inspection of seven randomly selected EM images for each experiment. Very few ⌬TM-RSV F-inserted liposomes were observed in the GS-5806-treated sample compared to those observed in the DMSO-or GSC-1-treated samples ( Fig. 2A) . On average, 4% Ϯ 3% of ⌬TM-RSV F-containing liposomes were observed in the GS-5806-treated sample, whereas 13% Ϯ 4% (DMSO) or 13% Ϯ 6% (GSC-1) of ⌬TM-RSV F-containing liposomes were observed in control samples. Interestingly, the average number of ⌬TM-RSV F molecules per liposome in the GS-5806-treated sample was 7 Ϯ 3, versus 25 Ϯ 10 in the DMSO-treated or GSC-1-treated samples. Similarly, the number of liposomes with ⌬TM-RSV F T400A molecules in GS-5806-treated samples was 8% Ϯ 3%, versus those in the DMSO-treated (14% Ϯ 3%) or GSC-1-treated (16% Ϯ 2%) samples (Fig. 2B) . Unlike ⌬TM-RSV F, the average numbers of ⌬TM-RSV F T400A molecules deposited per liposome (ϳ30) were similar for all three treatments. These observations are supported by liposome flotation experiments (see Fig. S3 in the supplemental material). Rosette formation and liposome association experiments show that GS-5806 interferes with the pre-to posttriggered conformational changes of ⌬TM-RSV F protein, similar to the conformational changes inhibited by influenza virus entry inhibitor (19) . Several RSV entry inhibitors representing diverse chemical classes (VP-14637, TMC-353121, and BMS-433771) have been reported in the literature (20) (21) (22) (23) . In the presence of these inhibitors (5-fold molar excess over protein), the number of rosettes formed was reduced by 2-to 5-fold compared to those with the DMSO control (see Fig. S4 in the supplemental material) . The binding sites for two of these entry inhibitors, TMC-353121 and BMS-433771, were identified by X-ray crystallography and chemical cross-linking methods and found to be close to the six-helix bundle of the RSV F protein (24, 25) . However, GS-5806 did not influence the formation of six-helix bundles when isolated peptides were mixed in the presence of GS-5806 (see Fig. S5A in the supplemental material). In addition, differential scanning calorimetry, isothermal titration calorimetry, and circular dichroism did not detect direct interaction of GS-5806 with isolated six-helix bundles (see Fig. S5B in the supplemental material) . These results suggest that GS-5806 does not interact with the isolated six-helix bundle the same as TMC-353121 or BMS-433771 compounds but still interferes with the transition of the RSV F protein from the pre-to posttriggered conformation to elicit that it is antiviral activity.
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